Abstract: The invention relates to cylindrical tunable fluidic lenses. The cylindrical optical power of the lenses may be continuously tuned within at least ±10 diopters, without inducing any significant spherical aberration, or any other significant aberrations. The lenses feature a geometry that produces minimal or no spherical defocus. These cylindrical tunable fluidic lenses could be used to induce and/or correct cylindrical optical aberrations in adaptive optical systems, particularly in ophthalmologic applications related to objective and automatic assessment of the refractive error of the eye, without the need of receiving feedback from the subjects.

Abstract: An apparatus has a central lens body for providing vision correction for a patient. The lens body has a central aperture and is configured as one of: a diffractive lens or a refractive lens. The lens body has at least one haptic extending from the lens body, and the central aperture has a form of a circular hole extending fully through the lens body when the apparatus is implanted in the eye. The lens body is formed from a substantially transparent material and the central aperture includes a darkened perimeter. The darkened perimeter of the central aperture includes a darkened internal wall extending through the lens body from an anterior surface to a posterior surface of the lens body.

Abstract: A photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient is disclosed herein. In one embodiment, a treatment laser is applied to a body portion of a patient using a painting technique, the treatment laser being configured to provide paint brush-type photodynamic therapy (PPDT) using the painting technique to the body portion of the patient by emitting light of a predetermined wavelength that is absorbed by tissue of the body portion of the patient to which a photosensitizer has been applied, the body portion of the patient being afflicted by a medical condition. The application of the treatment laser to the body portion of a patient using the painting technique treats the medical condition, reduces the symptoms associated with the medical condition, and/or alleviates the medical condition.

Abstract: A method of therapy for a tumor or other pathology by administering thermotherapy or a combination of thermotherapy and immunotherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and prevents tumor recurrence, either locally or at a different site, by boosting the patient's immune response both at the time of original therapy and/or for later therapy. The therapy may further include the administration of a vaccine.

Abstract: A method of treating, reducing, or alleviating a medical condition in a patient is disclosed herein. The method includes administering to a patient in need thereof a biocompatible drug comprising one or more antiviral medications together with one or more cell pathway inhibitors, the patient having at least one of a respiratory tract inflammatory disease, a central nervous system inflammatory disease, and vasculitis. The one or more antiviral medications preventing an attachment of viruses to cell walls, blocking a penetration of the viruses into cells, and/or inhibiting virus replication by damaging nucleic acids of the viruses. The one or more cell pathway inhibitors blocking an inflammatory response of inflamed tissue without inhibiting an immune response of the patient.

Abstract: An apparatus has a central lens body for providing vision correction for a patient. The lens body has a central aperture and is configured as one of: a diffractive lens or a refractive lens. The lens body has at least one haptic extending from the lens body, and the central aperture has a form of a circular hole extending fully through the lens body when the apparatus is implanted in the eye. The lens body is formed from a substantially transparent material and the central aperture includes a darkened perimeter. The darkened perimeter of the central aperture includes a darkened internal wall extending through the lens body from an anterior surface to a posterior surface of the lens body.

Abstract: A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) prior to implantation, treating an implant formed from donor corneal tissue or a tissue culture grown corneal stroma with a solution of sodium dodecyl sulfate (SDS), Triton X-100, benzalkonium chloride (BAK), Igepal, genipin, 100% glycerol, or alcohol for making the implant acellular, and for killing any bacteria, viruses, or parasites prior to implantation; (ii) implanting the implant into a recipient cornea; (iii) applying laser energy to the implant so as to modify the refractive power of the implant while being monitored using a Shack-Hartmann wavefront system so as to achieve a desired refractive power for the implant; and (iv) applying a cross-linking solution and irradiating the implant to cross-link the implant to prevent an immune response to the implant and/or rejection of the implant by a patient.

Abstract: Cancer treatment methods using thermotherapy and/or enhanced immunotherapy are disclosed herein. In one embodiment, the method comprising the steps of: (i) applying controlled thermal energy at 40-43° C. for a first predetermined time period to damage and weaken tumor cells of a tumor in a patient; (ii) administering pulsed high intensity focused ultrasound (pHIFU) in a first ultrasound mode to the tumor cells in the patient so as to damage the tumor cells without increasing the thermal energy; and (iii) administering low intensity focused ultrasound (LIFU) in a second ultrasound mode to further damage the tumor cells at a temperature of 39-43° C. for a second predetermined time period while performing observation of the tumor cells by ultrasonic thermometry.

Abstract: A method of lamellar corneal graft implantation is disclosed herein. In one or more embodiments, the method includes the steps of: (i) modifying a genetic component of a lamellar cornea or other tissue of an animal so that the lamellar cornea or other tissue of the animal can be used for human transplantation; (ii) decellularizing the lamellar cornea or other tissue ex vivo using chemical means; (iii) modifying a shape of the lamellar cornea or other tissue before or after transplantation; and (iv) applying a photosensitizer and ultraviolet radiation to the lamellar cornea or other tissue so as to crosslink collagen and intercellular proteins of the lamellar cornea or other tissue, kill the cells exposed to the photosensitizer, and eliminate an immune response by a host to the implanted lamellar cornea or the tissue.

Abstract: An ablatable corneal inlay for correction of refractive errors and/or presbyopia, and a method of correcting refractive errors and presbyopia in an eye of a patient using an ablatable corneal inlay is disclosed herein.

Abstract: Cancer treatment methods using thermotherapy and/or enhanced immunotherapy are disclosed herein. In one embodiment, the method comprising the steps of administering a plurality of nanoparticles to target a tumor in a patient, the nanoparticles being coated with an antitumor antibody, cell penetrating peptides (CPPs), and a polymer, and the nanoparticles containing medication and/or gene, and a dye or indicator in the polymer coating, at least some of the nanoparticles attaching to surface antigens of tumor cells so as to form a tumor cell/nanoparticle complex; exciting the nanoparticles using an ultrasound source generating an ultrasonic wave so as to peel off the polymer coating of the nanoparticles, thereby releasing the dye or indicator into the circulation of the patient and the medication and/or gene at the tumor site; and imaging a body region of the patient so as to detect the dye or indicator released into the circulation of the patient.

Abstract: A method for early stage pathology detection, location, imaging, evaluation, and treatment of cells and/or extracellular vesicles in the circulation.

Abstract: A telemedicine system with dynamic imaging is disclosed herein. In some embodiments, the telemedicine system comprises a laser imaging and treatment apparatus, and associated systems and methods that allow a physician (e.g., a surgeon) to perform laser surgical procedures on an eye structure or a body surface with a laser imaging and treatment apparatus disposed at a first (i.e. local) location from a control system disposed at a second (i.e. remote) location, e.g., a physician's office. Also, in some embodiments, communication between the laser imaging and treatment apparatus and control system is achieved via the Internet®. Further, in some embodiments, the telemedicine system includes a dynamic imaging system and/or a facial recognition system that verifies the identity of a patient, and is capable of being used for other important applications, such as tracking and analyzing trends in a disease process.

Abstract: A therapeutic vaccination method includes growing and harvesting viruses, bacteria, fungi, parasites, or tumor cells on a cell culture or other appropriate medium; killing the viruses, bacteria, fungi, parasites, or tumor cells in the cell culture or other appropriate medium with a dose of methylene blue; separating the dead viruses, bacteria, fungi, parasites, or tumor cells from a remainder of the cell culture or other appropriate medium using a filter and/or centrifuge; adding antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastic medications at non-toxic therapeutic concentrations to the dead viruses, bacteria, fungi, parasites, or tumor cells so as to form a therapeutic vaccine; and administering the therapeutic vaccine to a patient in need thereof to simultaneously produces a therapeutic response and a humoral and cellular immune response in the body of the patient without resulting in deleterious side effects to the patient.

Abstract: An apparatus has a central lens body for providing vision correction for a patient. The lens body has a central aperture and is configured as one of: a diffractive lens or a refractive lens. The lens body has at least one haptic extending from the lens body, and the central aperture has a form of a circular hole extending fully through the lens body when the apparatus is implanted in the eye. The lens body is formed from a substantially transparent material and the central aperture includes a darkened perimeter. The darkened perimeter of the central aperture includes a darkened internal wall extending through the lens body from an anterior surface to a posterior surface of the lens body.

Abstract: A system for preventing motion sickness resulting from virtual reality or augmented reality is disclosed herein. In one embodiment, the system includes a virtual reality or augmented reality headset configured to be worn by a user, the virtual reality or augmented reality headset configured to create an artificial environment and/or immersive environment for the user; at least one fluidic lens disposed between an eye of the user and a screen of the virtual reality or augmented reality headset; and a fluid control system operatively coupled to the at least one fluidic lens. In another embodiment, the system includes at least one tunable prism disposed between an eye of the user and a screen of the virtual reality or augmented reality headset, the at least one tunable prism configured to correct a convergence problem associated with the eye of the user.

Abstract: The invention relates to cylindrical tunable fluidic lenses. The cylindrical optical power of the lenses may be continuously tuned within at least ±10 diopters, without inducing any significant spherical aberration, or any other significant aberrations. The lenses feature a geometry that produces minimal or no spherical defocus. These cylindrical tunable fluidic lenses could be used to induce and/or correct cylindrical optical aberrations in adaptive optical systems, particularly in ophthalmologic applications related to objective and automatic assessment of the refractive error of the eye, without the need of receiving feedback from the subjects.

Abstract: A method of corneal and scleral inlay crosslinking and preservation is disclosed herein. The method includes cross-linking at least a portion of a donor cornea or a donor sclera so as to kill cellular elements in the portion of the donor cornea or the donor sclera, and make the portion of the donor cornea or the donor sclera less antigenic to a body portion of a recipient patient in which the portion of the donor cornea or the donor sclera is to be implanted; and storing the cross-linked donor cornea or the donor sclera for a long period of time prior to implanting the portion of the donor cornea or the donor sclera into the body portion of the recipient patient.

Abstract: A telemedicine system with dynamic imaging is disclosed herein. In some embodiments, the telemedicine system comprises a laser imaging and treatment apparatus, and associated systems and methods that allow a physician (e.g., a surgeon) to perform laser surgical procedures on an eye structure or a body surface with a laser imaging and treatment apparatus disposed at a first (i.e. local) location from a control system disposed at a second (i.e. remote) location, e.g., a physician's office. Also, in some embodiments, communication between the laser imaging and treatment apparatus and control system is achieved via the Internet®. Further, in some embodiments, the telemedicine system includes a dynamic imaging system and/or a facial recognition system that verifies the identity of a patient, and is capable of being used for other important applications, such as tracking and analyzing trends in a disease process.

Abstract: Cancer imaging methods and cancer treatment methods using thermotherapy and drug delivery are disclosed herein. In one embodiment, the temperature of heated tissue is determined from radio-frequency data from an ultrasound transducer based upon a change in backscattered energy of acoustic harmonics. In another embodiment, a plurality of nanocarriers containing an anti-tumor medication are administered to a patient, and are excited in a first non-thermal ultrasound mode and/or a second thermal ultrasound mode using an ultrasound source. In yet another embodiment, a plurality of nanoparticles are administered to a patient, then at least some of the nanoparticles are heated along with tissue at a site of a tumor, and a photoacoustic imaging unit is used to determine a temperature of the heated tissue at the site of the tumor.